Insulin glulisine in the management of diabetes.

Abstract

Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA(1c) seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.

• Authors: Satoru Yamada
• Journal: Diabetes, metabolic syndrome and obesity : targets and therapy (Diabetes Metab Syndr Obes) Vol. 2 Pg. 111-5 (Jul 07 2009) ISSN: 1178-7007 [Print] New Zealand
• PMID: 21437124 (Publication Type: Journal Article)